Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

por Mario, Boccadoro, Patrizia, Berto, Sara, Bringhen, Elena, Zamagni, Patrizia, Tosi, Nicola, Cascavilla, Nicola, Giuliani, Donato, Mannina, Renato, Zambello, Francesca, Patriarca, Vittorio, Montefusco, Mariella, Grasso, Francesco, Di Raimondo, Massimo, Offidani, Teresa, Petrucci Maria, Pellegrino, Musto
Publicado 2021

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

por Sonneveld, Pieter, Zweegman, Sonja, Cavo, Michele, Nasserinejad, Kazem, Broijl, Annemiek, Troia, Rosella, Pour, Ludek, Croockewit, Sandra, Corradini, Paolo, Patriarca, Francesca, Wu, Kalung, Droogendijk, Jolanda, Bos, Gerard, Hajek, Roman, Teresa Petrucci, Maria, Ypma, Paula, Zojer, Nicholas, Minnema, Monique C., Boccadoro, Mario
Publicado 2022